DOuble SEquential External Defibrillation for Refractory Ventricular Fibrillation (DOSE VF): study protocol for a random
- PDF / 811,523 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 104 Downloads / 188 Views
STUDY PROTOCOL
Open Access
DOuble SEquential External Defibrillation for Refractory Ventricular Fibrillation (DOSE VF): study protocol for a randomized controlled trial Ian R. Drennan1,2,3* , Paul Dorian4, Shelley McLeod5,6, Ruxandra Pinto7, Damon C. Scales3,7, Linda Turner1, Michael Feldman1,8, P. Richard Verbeek1,8, Laurie J. Morrison3,8 and Sheldon Cheskes1,2,3,8
Abstract Background: Despite high-quality cardiopulmonary resuscitation (CPR), early defibrillation, and antiarrhythmic medications, some patients remain in refractory ventricular fibrillation (VF) during out-of-hospital cardiac arrest. These patients have worse outcomes compared to patients who respond to initial treatment. Double sequential external defibrillation (DSED) and vector change (VC) defibrillation have been proposed as viable options for patients in refractory VF. However, the evidence supporting the use of novel defibrillation strategies is inconclusive. The objective of this study is to compare two novel therapeutic defibrillation strategies (DSED and VC) against standard defibrillation for patients with treatment refractory VF or pulseless ventricular tachycardia (pVT) during outof-hospital cardiac arrest. Research question: Among adult (≥ 18 years) patients presenting in refractory VF or pulseless ventricular tachycardia (pVT) during out-of-hospital cardiac arrest, does DSED or VC defibrillation result in greater rates of survival to hospital discharge compared to standard defibrillation? (Continued on next page)
* Correspondence: [email protected] 1 Sunnybrook Centre for Prehospital Medicine, Sunnybrook Health Sciences Centre, 77 Brown’s Line, Suite 100, Toronto, Ontario M8W 3S2, Canada 2 Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada Full list of author information is available at the end of the article © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Drennan et al. Trials
(2020) 21:977
Page 2 of 11
(Continued from previous page)
Methods: This will be a three
Data Loading...
